10526-1-AP

antibody from Proteintech Group

Targeting: RRM1

Provider product page for 10526-1-AP

Western blot

ELISA

Immunocytochemistry

Immunoprecipitation

Immunohistochemistry

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [49]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]
Immunoprecipitation [1]
Immunohistochemistry [2]

Submit

Product number: 10526-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#10526-1-AP, RRID:AB_2180372
Product name: RRM1 antibody
Antibody type: Polyclonal
Description: KD/KO validated RRM1 antibody (Cat. #10526-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat, monkey and has been validated for the following applications: FC, IF, IHC, IP, WB, ELISA.
Reactivity: Human, Mouse, Rat, Simian
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

RRM1 protein structure - 10526-1-AP shown in red.

Submitted references Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.

Lin X, Tan Y, Pan L, Tian Z, Lin L, Su M, Ou G, Chen Y
Cancer chemotherapy and pharmacology 2024 Mar;93(3):237-251

Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas.

Yin J, Wang X, Ge X, Ding F, Shi Z, Ge Z, Huang G, Zhao N, Chen D, Zhang J, Agnihotri S, Cao Y, Ji J, Lin F, Wang Q, Zhou Q, Wang X, You Y, Lu Z, Qian X
Nature communications 2023 Sep 22;14(1):5913

3-AP inhibits the growth of human osteosarcoma by decreasing the activity of the iron-dependent pathway.

Huang S, Zhang D, Yi X, Liu C, Jian C, Yu A
Medical oncology (Northwood, London, England) 2023 Nov 11;40(12):353

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling.

Zhou X, Luo J, Xie H, Wei Z, Li T, Liu J, Liao X, Zhu G, Peng T
Cell death discovery 2022 Oct 15;8(1):418

Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma.

Wang Z, Fu Y, Xia A, Chen C, Qu J, Xu G, Zou X, Wang Q, Wang S
Cell proliferation 2021 Oct;54(10):e13117

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.

Chun JW, Lee B, Park WS, Han N, Hong EK, Park EY, Han SS, Park SJ, Kim TH, Lee WJ, Woo SM
Journal of clinical medicine 2021 Oct 11;10(20)

Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.

Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, Sun Q, Zhang Z, Liu W, Xu W, Ji S, Yu X, Xu X, Qin Y
American journal of cancer research 2020;10(4):1182-1193

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.

Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R
International journal of cancer 2020 Jun 1;146(11):3087-3097

A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).

Fukumoto SI, Oizumi S, Harada M, Sukoh N, Nakano K, Fuke S, Sakakibara-Konishi J, Takamura K, Ito K, Fujita Y, Nishigaki Y, Harada T, Akie K, Kinoshita I, Amano T, Isobe H, Dosaka-Akita H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group
Cancer chemotherapy and pharmacology 2020 Jul;86(1):117-127

Integrative Analysis Reveals Across-Cancer Expression Patterns and Clinical Relevance of Ribonucleotide Reductase in Human Cancers.

Ding Y, Zhong T, Wang M, Xiang X, Ren G, Jia Z, Lin Q, Liu Q, Dong J, Li L, Li X, Jiang H, Zhu L, Li H, Shen D, Teng L, Li C, Shao J
Frontiers in oncology 2019;9:956

Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.

Sun Q, Xu W, Ji S, Qin Y, Liu W, Hu Q, Zhang Z, Liu M, Yu X, Xu X
Cancer cell international 2019;19:49

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.

Hu Q, Qin Y, Zhang B, Liang C, Ji S, Shi S, Xu W, Xiang J, Liang D, Ni Q, Yu X, Xu J
Oncology reports 2017 Oct;38(4):2069-2077

DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.

Woo SM, Yoon KA, Hong EK, Park WS, Han SS, Park SJ, Joo J, Park EY, Lee JH, Kim YH, Kim TH, Lee WJ
Oncotarget 2017 Oct 6;8(46):81394-81404

Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer.

Tóth C, Sükösd F, Valicsek E, Herpel E, Schirmacher P, Renner M, Mader C, Tiszlavicz L, Kriegsmann J
International journal of molecular medicine 2017 Nov;40(5):1457-1465

Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.

Liu D, Nakashima N, Nakano J, Tarumi S, Matsuura N, Nakano T, Nii K, Tokunaga Y, Go T, Yokomise H
Anticancer research 2017 May;37(5):2501-2507

Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.

Matsumura N, Nakamura Y, Kohjimoto Y, Nishizawa S, Kikkawa K, Iba A, Kodama Y, Hara I
International journal of urology : official journal of the Japanese Urological Association 2017 Mar;24(3):230-235

Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.

Lou M, Liu Q, Ren G, Zeng J, Xiang X, Ding Y, Lin Q, Zhong T, Liu X, Zhu L, Qi H, Shen J, Li H, Shao J
The Journal of biological chemistry 2017 Jun 2;292(22):9136-9149

Impact of molecular profiling on overall survival of patients with advanced ovarian cancer.

Herzog TJ, Spetzler D, Xiao N, Burnett K, Maney T, Voss A, Reddy S, Burger R, Krivak T, Powell M, Friedlander M, McGuire W
Oncotarget 2016 Apr 12;7(15):19840-9

Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.

Millis SZ, Ejadi S, Demeure MJ
Biomarkers in cancer 2015;7:69-76

Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.

Popovtzer A, Sarfaty M, Limon D, Marshack G, Perlow E, Dvir A, Soussan-Gutman L, Stemmer SM
BioMed research international 2015;2015:614845

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.

Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH, Moon KC
PloS one 2015;10(7):e0133371

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.

Watanabe Y, Shiraishi K, Takahashi F, Yoshida A, Suzuki K, Asamura H, Takeuchi M, Furuta K, Tsuta K
Histopathology 2015 Jun;66(7):939-48

Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.

Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I
The Journal of thoracic and cardiovascular surgery 2015 Jun;149(6):1539-46.e1

Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.

Millis SZ, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang NJ
Clinical genitourinary cancer 2015 Feb;13(1):e37-49

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.

Zimling ZG, Santoni-Rugiu E, Bech C, Sørensen JB
Anticancer research 2015 Dec;35(12):6731-8

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).

Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 15;21(24):5563-77

Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

Dong X, Hao Y, Wei Y, Yin Q, Du J, Zhao X
PloS one 2014;9(3):e92320

Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.

Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Nov 1;20(21):5435-45

Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer.

Okimoto T, Tsubata Y, Sutani A, Fuchita H, Koba N, Hotta T, Hamaguchi M, Miura K, Hamaguchi S, Ohe M, Kuraki T, Harada Y, Maruyama R, Miyamoto N, Kishimoto K, Isobe T
Anticancer research 2014 Jun;34(6):2755-61

Cell-based delivery of dATP via gap junctions enhances cardiac contractility.

Lundy SD, Murphy SA, Dupras SK, Dai J, Murry CE, Laflamme MA, Regnier M
Journal of molecular and cellular cardiology 2014 Jul;72:350-9

Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Sørensen JB
Histopathology 2014 Feb;64(3):412-20

Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.

Wang Q, Liu X, Zhou J, Huang Y, Zhang S, Shen J, Loera S, Yuan X, Chen W, Jin M, Shibata S, Liu Y, Chu P, Wang L, Yen Y
PloS one 2013;8(7):e70191

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.

Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J
Cancer management and research 2013;5:327-36

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.

Murata A, Amano R, Yamada N, Kimura K, Yashiro M, Nakata B, Hirakawa K
World journal of surgical oncology 2013 May 27;11:117

Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery.

Yokomise H, Liu D, Chang S, Go T, Ishikawa S, Misaki N, Nakashima N
Anticancer research 2013 Mar;33(3):1107-15

Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Ravn J, Sørensen JB
European journal of cancer (Oxford, England : 1990) 2013 Jul;49(11):2494-503

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Farris AB 3rd, Maithel SK
Cancer 2013 Jan 15;119(2):454-62

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.

Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Maithel SK
Cancer 2013 Jan 15;119(2):445-53

The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.

Nie X, Cheng G, Ai B, Zhang S
Cancer biomarkers : section A of Disease markers 2013 Jan 1;13(6):433-40

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.

Vilmar AC, Santoni-Rugiu E, Sorensen JB
Annals of oncology : official journal of the European Society for Medical Oncology 2013 Feb;24(2):309-314

Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.

Yokomise H, Liu D, Ishikawa S, Go T, Gotoh M, Okuda M, Tarumi S, Kasai Y, Matsuura N
Anticancer research 2013 Dec;33(12):5597-602

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.

Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB
Lung cancer (Amsterdam, Netherlands) 2012 Mar;75(3):306-12

Zajchowski DA, Karlan BY, Shawver LK
Molecular cancer therapeutics 2012 Feb;11(2):492-502

In vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) in solid pseudopapillary tumor of the pancreas.

Kang CM, Kim H, Cho Y, Kim YS, Hwang HK, Choi HJ, Lee WJ
Pancreas 2012 Apr;41(3):498-500

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

Jordheim LP, Sève P, Trédan O, Dumontet C
The Lancet. Oncology 2011 Jul;12(7):693-702

Remodeling of the metabolome during early frog development.

Vastag L, Jorgensen P, Peshkin L, Wei R, Rabinowitz JD, Kirschner MW
PloS one 2011 Feb 4;6(2):e16881

The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Lee JJ, Maeng CH, Baek SK, Kim GY, Yoo JH, Choi CW, Kim YH, Kwak YT, Kim DH, Lee YK, Kim JB, Kim SY
Lung cancer (Amsterdam, Netherlands) 2010 Nov;70(2):205-10

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.

Wang X, Zhao J, Yang L, Mao L, An T, Bai H, Wang S, Liu X, Feng G, Wang J
Medical oncology (Northwood, London, England) 2010 Jun;27(2):484-90

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G
The New England journal of medicine 2007 Feb 22;356(8):800-8

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: HeLa cells were subjected to SDS PAGE followed by western blot with 10526-1-AP(RRM1 antibody) at dilution of 1:2000
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunofluorescent analysis of Hela cells, using RRM1 antibody 10526-1-AP at 1:50 dilution and Rhodamine-labeled goat anti-rabbit IgG (red). Blue pseudocolor = DAPI (fluorescent DNA dye).
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: IP Result of anti-RRM1 (IP:10526-1-AP, 5ug; Detection:10526-1-AP 1:800) with K-562 cells lysate 8000ug.
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human colon cancer using 10526-1-AP(RRM1 antibody) at dilution of 1:100 (under 10x lens)
Sample type: tissue

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human colon cancer using 10526-1-AP(RRM1 antibody) at dilution of 1:100 (under 40x lens)
Sample type: tissue